Preclinical Evaluation of Gemcitabine Combination Regimens for Application in Acute Myeloid Leukemia

The DNA antimetabolite gemcitabine is an anticancer agent with shown preclinical and clinical utility and a low toxicity profile. In this study, we sought to identify and optimize drug partners for binary and tertiary combinations with gemcitabine for use in the treatment of acute myelogenous leukemia (AML). Drug interaction was assessed by growth inhibition assay with metabolic end points. The combination index method was used to evaluate combinations of gemcitabine with fludarabine, paclitaxel, chlorambucil, doxorubicin, mitoxantrone, and SN-38 in U937 human AML cells. A three-dimensional method was used to determine the effect of dose ratio and schedule on drug interaction. Mechanisms underlying interactions related to cell cycle effects and apoptosis were assessed by flow cytometric and caspase-3 and -7 assays, respectively. The most synergistic binary combination was gemcitabine + fludarabine. The most synergistic tertiary combination was gemcitabine + fludarabine + paclitaxel, where the interaction was sequence dependent with paclitaxel given before gemcitabine + fludarabine, producing a 2-fold increase in synergy. Cell cycle analysis did not reveal a significant G2-M arrest, suggesting that the synergistic effect of paclitaxel in this combination, which produced the greatest caspase activation, might be independent of microtubule stabilization. In contrast, the gemcitabine + fludarabine + mitoxantrone combination was synergistic and schedule independent. Moreover, few ratios of gemcitabine + fludarabine to mitoxantrone were antagonistic, which could be important for clinical translation. In conclusion, synergistic interactions with gemcitabine occurred with several drugs, the most promising being gemcitabine + fludarabine, gemcitabine + fludarabine + paclitaxel, and gemcitabine + fludarabine + mitoxantrone. These findings provided a rationale for clinical trials of gemcitabine + fludarabine and gemcitabine + mitoxantrone where responses were observed in heavily pretreated AML patients.

[1]  W. Fan,et al.  Possible mechanisms of paclitaxel-induced apoptosis. , 1999, Biochemical pharmacology.

[2]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[3]  C. Nabhan,et al.  Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. , 2002, Molecular cancer therapeutics.

[4]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[5]  R. Momparler,et al.  Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. , 1995, Leukemia research.

[6]  N. Saijo,et al.  In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. , 1997, Seminars in oncology.

[7]  D. Amadori,et al.  Schedule‐dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines , 1999, International journal of cancer.

[8]  G. Peters,et al.  Combination chemotherapy studies with gemcitabine. , 1997, Seminars in oncology.

[9]  S. Tura,et al.  In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. , 1999, Haematologica.

[10]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[11]  E. Estey,et al.  Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Saijo,et al.  Evaluation of synergism by a novel three‐dimensional model for the combined action of cisplatin and etoposide on the growth of a human small‐cell lung‐cancer cell line, SBC‐3 , 1997, International journal of cancer.

[13]  E. Estey,et al.  Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. , 2003, Leukemia research.

[14]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  G. Peters,et al.  Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. , 1999, Biochemical pharmacology.

[16]  W. Plunkett,et al.  Cellular and Clinical Pharmacology of Fludarabine , 2002, Clinical pharmacokinetics.

[17]  G. Peters,et al.  Basis for effective combination cancer chemotherapy with antimetabolites. , 2000, Pharmacology & therapeutics.

[18]  D. Niedzwiecki,et al.  Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma , 2004, Cancer.

[19]  R. Fisher,et al.  Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Mark R. Green,et al.  Synergistic interaction between topotecan and microtubule-interfering agents , 2001, Cancer Chemotherapy and Pharmacology.

[21]  G. Rosner,et al.  Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Y. Kano,et al.  Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. , 1992, Leukemia.

[23]  G. Rosner,et al.  Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Plunkett,et al.  Pharmacology of purine nucleoside analogues. , 1996, Hematology and cell therapy.